Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

N-chlorotaurine Inactivates Acanthamoeba and Candida albicans in the Porcine Ex Vivo Corneal Infection Model

Teuchner, Barbara MD*; Wibmer, Idris D. MD; Schaumann, Philipp MD; Seifarth, Christof MSc*; Walochnik, Julia PhD§; Nagl, Markus MD

doi: 10.1097/ICO.0000000000001927
Basic Investigation

Purpose: N-chlorotaurine (NCT) is an anti-infective belonging to the class of chloramines and an investigative drug for the topical treatment of keratoconjunctivitis. The aim of the present study was to demonstrate its efficacy against Acanthamoeba and Candida in corneas infected ex vivo.

Methods: Corneal buttons from porcine eyes were contaminated with Acanthamoeba castellanii trophozoites or Candida albicans Centraalbureau voor Schimmelcultures 5982 and incubated for 7 and 3 days, respectively. Subsequently, they were treated with 1% NCT for 5 to 120 minutes. After further incubation for 2 days in the absence of NCT in tests with A. castellanii, the buttons were homogenized, and the amoebae grown for a further 5 days before they were counted in a light microscope. For C. albicans, quantitative cultures were performed from corneal homogenates.

Results: Incubation of 120 minutes in NCT completely inhibited the regrowth of A. castellanii and reduced the number of C. albicans colony-forming unit counts by 4 log10. In addition, at 60 minutes, significant reductions of both pathogens could be observed. Histology showed penetration of pathogens into the stroma of the corneal buttons.

Conclusions: NCT inactivates A. castellanii and C. albicans in corneal tissue.

*Department of Ophthalmology, Medical University of Innsbruck, Innsbruck, Austria;

Division of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria;

Department of Ophthalmology, University Hospital Regensburg, Regensburg, Germany; and

§Molecular Parasitology, Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.

Correspondence: Markus Nagl, MD, Division of Hygiene and Medical Microbiology, Medical University of Innsbruck, Schöpfstr, 41 A-6020 Innsbruck, Austria (e-mail:

This study was supported by the Austrian Science Fund, grant no. KLI459-B30.

The authors have no conflicts of interest to disclose.

J. Walochnik and M. Nagl are co-senior authors.

Received December 31, 2018

Received in revised form January 30, 2019

Accepted February 04, 2019

Online date: March 28, 2019

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.